Pfizer presented Phase 3 data for Litfulo (a daily pill) in vitiligo, reporting significant improvements in skin pigment measures in two pivotal studies. The results were presented during the European Academy of Dermatology and Venereology annual meeting. Pfizer framed the program as positioning Litfulo for upcoming FDA and EMA submissions. The therapy would compete against an Incyte topical treatment that remains the only FDA-approved option for vitiligo. The disclosure adds momentum to a market where clinicians and patients increasingly look for systemic, convenient regimens that can complement or replace topical approaches—particularly in disease subtypes with broader body involvement.